SUBSCRIBE
SUBSCRIBE

Depression

Pictured: Anxious man with his head in his hands/i
Drug Development
Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward
Engrail Therapeutics’ latest financing round will give it enough funds to advance its candidates for neuropsychiatric and neurodevelopmental disorders through clinical development.
March 19, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A suited arm pointing a dart at a bullse
Deals
Psychedelics, Solid Tumors Will Be Key Focuses for Investors in 2024
After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
March 5, 2024
 · 
5 min read
 · 
Heather McKenzie
Load More
PRESS RELEASES
Press Releases
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
June 12, 2025
 · 
6 min read
Press Releases
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
June 9, 2025
 · 
9 min read
Press Releases
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
June 6, 2025
 · 
3 min read
Press Releases
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
June 3, 2025
 · 
10 min read
Press Releases
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
June 3, 2025
 · 
4 min read
Press Releases
Beckley Psytech announces positive topline data from Part 2 of its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) in combination with SSRIs for treatment resistant depression
May 20, 2025
 · 
5 min read
Press Releases
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
May 7, 2025
 · 
7 min read
Press Releases
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
May 2, 2025
 · 
8 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression
May 1, 2025
 · 
7 min read
Press Releases
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
April 22, 2025
 · 
6 min read
Press Releases
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
April 22, 2025
 · 
5 min read
Press Releases
New Landmark Study Reveals Brain Blood Flow as Key Biomarker in Depression--Amen Clinics Plays Pivotal Role
April 8, 2025
 · 
2 min read
Press Releases
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
April 1, 2025
 · 
6 min read
Press Releases
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
April 1, 2025
 · 
4 min read
Press Releases
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
March 12, 2025
 · 
5 min read
Press Releases
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies
February 24, 2025
 · 
3 min read
Press Releases
Syra Health Announces Positive Preliminary Results from Syrenity Study Led by Indiana University
February 19, 2025
 · 
5 min read
Press Releases
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
February 13, 2025
 · 
6 min read
Press Releases
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
January 30, 2025
 · 
6 min read
Press Releases
NeuroKaire Secures $10 Million to Advance Precision Medicine for Mental Health
December 17, 2024
 · 
1 min read
Load More